IntroductionHerpes Zoster (HZ), or shingles, is a skin disease characterized by a unilateral, dermatomal and often painful vesicular eruption. After primary varicella zoster virus (VZV) infection, the virus remains latent in the dorsal or cranial sensory ganglia. The epidemic typically results from reactivation of latent VZV.1 Herpes zoster (HZ) occurs years or decades after primary VZV infection, known clinically as chickenpox and, in many cases, as chicken pox.1 HZ it is primarily a disease in the elderly or individuals with weakened immune systems. It is estimated that VZV is responsible for four cases of herpes zoster infection per thousand people per year, of which approximately 50% affect patients aged 50 years or older.1, 2 The number of cases tends to increase proportionally with age of age. Approximately 10-20% of the US population will develop HZ, and approximately 50% are expected to develop HZ in their lifetime by age 85.1,2 Although the number of people in the United States who contract HZ Chickenpox has increased dramatically every year due to vaccinations, doctors need to be trained on preventative strategies along with current treatment options. This article addresses the related signs and symptoms of HZ, as well as existing treatments of acute HZ and postherpetic neuralgia. Outlines current treatment strategies, along with shortages of newer medications and procedure implementations. Clinical presentation Patients with HZ typically present with a characteristic, distinctive unilateral vesicular rash, localized in the dermatomal distribution, which is often followed by intense localized prodromal pain. In rare cases, it is about... half the paper... supplier experience, management is often insufficient. Better application of available treatment options, use of up-to-date resources, and a complex approach to the management of PHN can play a superior role in treatment. Primary care is at the forefront of patient care, diagnosis and treatment. It plays an essential and crucial role in the development and execution of the PHN treatment plan. Patient treatment could be influenced by multiple factors, ranging from drug treatment compliance and side effects to the cost of the drug. Sufficient management should be achieved by starting with a single medication, titrating additional treatment options as needed. Severe cases of PHN should be followed by the use of topical anesthetic agents and paravertebral injections, if other therapeutic means fail. Systematized and thoughtful therapy for post-herpetic neuralgia will ensure sufficient pain relief and reduce the risk of post-herpetic neuralgia.